ABBV vs TBPH · P/E 81, rev $16.99B vs P/E 7.5, rev $38.4M
AbbVie Inc (ABBV) versus Theravance Biopharma Inc (TBPH) — a side-by-side from cached financials, not a winner call.
AbbVie Inc (ABBV) is a drug manufacturers - general company listed on US. It is led by Rob Michael.
Theravance Biopharma Inc (TBPH) is a biotechnology company listed on NASDAQ.
Latest reported ABBV revenue for 2026-06-30 was $16.99B. Net income was $3.61B. Revenue was up 13.3% from 2026-03-31 to 2026-06-30. ABBV currently screens at market cap $334.34B and trailing P/E 80.5.
Latest reported TBPH revenue for 2026-06-30 was $38.4M. Net income was -$10.8M. TBPH currently screens at market cap $861.5M and trailing P/E 7.5.
ABBV currently screens at market cap $334.34B and trailing P/E 80.5. TBPH currently screens at market cap $861.5M and trailing P/E 7.5.
Not investment advice. Open the ABBV and TBPH stock pages for the full models.
Not investment advice.